NCCN Guidelines® Panel: Melanoma

Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed YERVOY® (ipilimumab) clinical data that has been presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting to the NCCN® Melanoma Panel for your consideration. This phase 3 randomized study evaluated ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for the treatment of patients with resected high-risk melanoma in the adjuvant setting.1

FDA Clearance YERVOY® (ipilimumab) (indications in melanoma): The FDA-approved ipilimumab on October 28, 2015 for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.2 Ipilimumab was also approved on March 25, 2011 for the treatment of unresectable or metastatic melanoma.2

Rationale: The enclosed presentation is an unplanned descriptive analysis reporting the safety and three year relapse-free survival of the two ipilimumab arms (3 and 10 mg/kg).1

The following resources are included for your review.


Thank you for your consideration.

Sincerely,

Awny Farajallah, MD, FACP
Vice President, Head US Medical Oncology
Bristol-Myers Squibb Company